03. 14. 2023

Protocol Design and Investigator Site Selection: Type 2 Diabetes Mellitus (T2DM)

Read more
03. 01. 2023

Almost one in five clinical trials recruit only a single patient. How can the industry tackle this issue?

Before heading to SCOPE 2023 this month, we released our latest analysis investigating enrollment data from 173 cancer clinical trials over the last three years. Our analysis uncovered chronic challenges in clinical development, finding that 2,298 of 11,826 investigator sites (nearly one in five) have only enrolled a single patient.

Read more
12. 20. 2022

Collagen Clinical Development: Beyond Cosmetics

As the most abundant protein in the human body and a crucial component of connective tissue, collagen is crucial for the body’s strength and structure. However, part of the natural aging process is collagen depletion. Today, scientists around the world are investigating how collagen can help to mitigate age-related conditions. The past decade has witnessed a growing interest in how collagen-based therapies could treat diseases, prevent complications, and benefit the health of aging people.

Read more
10. 18. 2022

To improve patient centricity in clinical development, we need to move past ‘gut-feeling’ and towards a data-led approach

Clinical development has faced several years of disruption from recent global events, from the pandemic to the ongoing war in Ukraine and now a looming economic crisis. Given the scale of such events, it’s more important than ever to be able to accurately predict outcomes for clinical trials and minimize patient burden and R&D costs. This requires moving from a perception-led approach to a data-led approach. It means learning from the past and present by simulating the future. And designing smarter trials that lead to faster cures.

Read more
09. 21. 2022

Enabling Patient Centricity by Improving Diversity in Clinical Development

Our founder and CEO, Dr Gen Li was recently invited for a discussion with Xtelligent Healthcare Media, to explore our recent data around diversity in clinical trials. The conversation raised some interesting questions about diversity and decentralization in clinical trials. We’ve been reflecting on the issues raised in the discussion, and the strategies the clinical development industry can take to ensure patients who are enrolled in trials are representative of the patients who will receive the drug in the real-world.

Read more